US5889030A - Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen - Google Patents

Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen Download PDF

Info

Publication number
US5889030A
US5889030A US08/873,924 US87392497A US5889030A US 5889030 A US5889030 A US 5889030A US 87392497 A US87392497 A US 87392497A US 5889030 A US5889030 A US 5889030A
Authority
US
United States
Prior art keywords
pranoprofen
aqueous solution
container
antioxidant
stabilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/873,924
Inventor
Koji Doi
Hisako Sawa
Yoshie Ozaki
Yoshiyuki Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Mitsubishi Pharma Corp
Original Assignee
Senju Pharmaceutical Co Ltd
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Welfide Corp filed Critical Senju Pharmaceutical Co Ltd
Priority to US08/873,924 priority Critical patent/US5889030A/en
Application granted granted Critical
Publication of US5889030A publication Critical patent/US5889030A/en
Assigned to WELFIDE CORPORATION reassignment WELFIDE CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
Assigned to MITSUBISHI PHARMA CORPORATION reassignment MITSUBISHI PHARMA CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). Assignors: WELFIDE CORPORATION
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
    • Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article
    • Y10T428/1393—Multilayer [continuous layer]

Definitions

  • the present invention relates to a method for stabilizing pranoprofen having anti-inflammatory activity, in an aqueous solution of pranoprofen, and to a liquid preparation comprising, as an active ingredient, pranoprofen which is stabilized by adding an antioxidant.
  • Pranoprofen having a chemical name of ⁇ -methyl-5H- 1!benzopyrano 2,3-b!pyridine-7-acetic acid exhibits prominent anti-inflammatory action, analgesic action and antipyretic action. It is a non-steroidal anti-inflammatory drug having a wider safety margin, and is commercially available by the product name of Niflan (trademark). The properties and production method thereof are described in U.S. Pat. No. 3,931,295.
  • pranoprofen is unstable in an aqueous solution state, particularly to light, and is gradually decomposed during long-term preservation.
  • Another object of the present invention is to provide an aqueous solution of pranoprofen, wherein decomposition of pranoprofen is suppressed.
  • decomposition of pranoprofen can be markedly suppressed by placing an aqueous solution of pranoprofen in coexistence with an antioxidant, or placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen.
  • a method for stabilizing pranoprofen comprising placing an aqueous solution of pranoprofen in coexistence with an antioxidant.
  • a method for stabilizing pranoprofen according to (1) comprising adding an antioxidant to an aqueous solution of pranoprofen.
  • a method for stabilizing pranoprofen according to (2) comprising adding an antioxidant at a ratio to pranoprofen of 0.0002-5.0 by weight.
  • a method for stabilizing pranoprofen according to (1) comprising sealing an aqueous solution of pranoprofen in a container formed from a material comprising an antioxidant.
  • a method for stabilizing pranoprofen according to (4) comprising adding an antioxidant to a material of the container at a ratio to the material of 0.0001-0.005 by weight.
  • alkylphenol is at least one compound selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
  • (9) A method for stabilizing pranoprofen according to (7), wherein the benzopyran derivative is at least one member selected from the group consisting of L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! and salts thereof.
  • a method for stabilizing pranoprofen comprising placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen.
  • a method for stabilizing pranoprofen according to (13), comprising sealing a container, in which an aqueous solution of pranoprofen has been sealed, in a container or enclosing the container with a sheet, together with a deoxygenating agent.
  • a method for stabilizing pranoprofen according to (13), comprising sealing an aqueous solution of pranoprofen in a container having a low oxygen permeability or enclosing the solution with a sheet having a low oxygen permeability.
  • the first mode of the stabilizing method of the present invention is placing an aqueous solution of pranoprofen in coexistence with an antioxidant, which is realized by, for example, (i) adding an antioxidant to an aqueous solution of pranoprofen (Mode I) or (ii) sealing an aqueous solution of pranoprofen in a container formed from a material comprising an antioxidant (Mode II).
  • an antioxidant for example, (i) adding an antioxidant to an aqueous solution of pranoprofen (Mode I) or (ii) sealing an aqueous solution of pranoprofen in a container formed from a material comprising an antioxidant (Mode II).
  • Modes I and II may be used in combination.
  • the antioxidant to be used in Mode I includes, for example, alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.
  • alkylphenol examples include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), n-propyl gallate and catechol, with preference given to BHT and BHA.
  • benzopyran derivative examples include tocopherol, tocol, L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! and salts thereof, with preference given to L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! potassium salt (EPC-K 1 ).
  • Amino acid is, for example, methionine, tryptophan or histidine, with preference given to methionine and tryptophan.
  • the antioxidant When an antioxidant is added to an aqueous solution of pranoprofen according to Mode I, the antioxidant is generally added at a ratio to pranoprofen of 0.0002-5.0 by weight, preferably 0.002-2.5 by weight.
  • the container is, for example, generally a plastic container such as the one composed of polyolefin e.g. polyethylene (PE) and polypropylene (PP)!, with preference given to the one composed of PP.
  • PE polyethylene
  • PP polypropylene
  • An antioxidant is added to the material of the container at a ratio to the material of, for example, 0.0001-0.005 by weight, preferably 0.0005-0.005 by weight.
  • the antioxidant to be used is, for example, a phenol such as alkylphenol, alkyldiphenol or thiobisalkylphenol.
  • alkylphenol examples include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), n-propyl gallate, stearyl ⁇ -(3,5-di-t-butyl-4-hydroxyphenyl)propionate, tetrakis 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyloxymethyl!methane, 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1H,2H,3H-triazine-2,4,6-trione, 1,3,5-tris (3,5-di-tert-butyl-4-hydroxybenzyl)-2,4,6-trimethyl!benzene and 3,9-bis 2-(3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy)-1,1-dimethylethyl!-2,4,8,10-tetraoxaspiro 5.5
  • alkyldiphenol examples include 2,2'-methylenebis(4-methyl-6-tert-butylphenol), 4,4'-butylidenebis(2-tert-butyl-5-methylphenol) and 2-tert-butyl-6-(3-tert-butyl-2-hydroxy-5-methylbenzyl)-4-methylphenyl acrylate.
  • thiobisalkylphenol examples include 4,4'-thiobis(2-tert-butyl-5-methylphenol).
  • the second mode of the stabilizing method of the present invention is placing an aqueous solution of pranoprofen under the conditions of limited oxygen supply.
  • a container containing an aqueous solution of pranoprofen sealed therein is sealed in another container or enclosed with a sheet in coexistence with a deoxygenating agent (Mode III), or an aqueous solution of pranoprofen is sealed in a container having a low oxygen permeability, or enclosed with a sheet having a low oxygen permeability (Mode IV).
  • the container for sealing an aqueous solution of pranoprofen is subject to no particular limitation as long as it can seal an aqueous solution of pranoprofen, and is preferably exemplified by a container formed from a material containing an antioxidant, such as those exemplified for the above-mentioned Mode II, and a container having a low oxygen permeability to be mentioned below.
  • the deoxygenating agent to be used in Mode III is exemplified by iron powder, iron oxide, ascorbic acid and catechol, with preference given to iron oxide.
  • the deoxygenating agent is preferably packed in a bag etc. made of an oxygen-permeable material and put to use.
  • the container and the sheet to enclose a container, in which an aqueous solution of pranoprofen has been sealed, together with a deoxygenating agent according to Mode III, are not subject to any particular limitation as long as they can enclose both the container, in which an aqueous solution of pranoprofen has been sealed, and a deoxygenating agent in such a manner that the outside air is shut off from them.
  • Examples of the container include plastic containers and glass containers, and examples of the sheet include plastic sheets and aluminum sheets.
  • the materials for such containers and sheets may contain an antioxidant, as exemplified in the above-mentioned Mode II, or may have a low oxygen permeability as discussed below. Also, an antioxidant may be added to an aqueous solution of pranoprofen in Mode III.
  • the container and the sheet having low oxygen permeability which are to be used in Mode IV, are preferably made from a material having an oxygen permeability of not more than 120 cc/m 2 ⁇ 24 hr ⁇ atom 20° C. ⁇ 90% relative humidity (RH), thickness of material 25 ⁇ m!, preferably not more than 70 cc/m 2 ⁇ 24 hr ⁇ atom (20° C. ⁇ 90% RH, thickness of material 25 ⁇ m), such as those made from acrylonitrile resins e.g. acrylonitrile styrene (AS) and acrylonitrile butadiene styrene (ABS)! and polyethylene terephthalate (PET), with particular preference given to those made from PET.
  • acrylonitrile resins e.g. acrylonitrile styrene (AS) and acrylonitrile butadiene styrene (ABS)!
  • PET polyethylene terephthalate
  • the solvent to be used to prepare a liquid preparation and an aqueous solution of pranoprofen of the present invention is exemplified by sterile purified water, in particular, distilled water for injection.
  • the concentration of the active ingredient pranoprofen is generally 0.01-2.0 w/v %, preferably 0.05-1.0 w/v %, which is increased or decreased as appropriate according to the object of use.
  • the antioxidant to be used for the liquid preparation of pranoprofen of the present invention is exemplified by those mentioned for Mode I.
  • the liquid preparation of the present invention may further contain various additives on demand, such as buffers, isotonizing agents, solubilizing agents, preservatives, thickeners, chelating agents, pH adjusting agents and aromatic agents.
  • various additives on demand such as buffers, isotonizing agents, solubilizing agents, preservatives, thickeners, chelating agents, pH adjusting agents and aromatic agents.
  • buffer examples include phosphate buffer (e.g. sodium dihydrogenphosphate-disodium hydrogenphosphate and potassium dihydrogenphosphate-potassium hydroxide), borate buffer (e.g. boric acid-sodium tetraborate), citrate buffer (e.g. sodium citrate-sodium hydroxide), tartrate buffer (e.g. tartaric acid-sodium tartrate), acetate buffer (e.g. acetic acid-sodium acetate), carbonate buffer (e.g. sodium carbonate-citric acid and sodium carbonate-boric acid) and amino acid (e.g. sodium glutamate and ⁇ -aminocaproic acid).
  • phosphate buffer e.g. sodium dihydrogenphosphate-disodium hydrogenphosphate and potassium dihydrogenphosphate-potassium hydroxide
  • borate buffer e.g. boric acid-sodium tetraborate
  • citrate buffer e.g. sodium citrate-sodium hydroxide
  • borate buffer acetate buffer or carbonate buffer be used to decrease irritation.
  • isotonizing agent examples include saccharides such as sorbitol, glucose and mannitol, polyhydric alcohols such as glycerol and propylene glycol, salts such as sodium chloride and sodium tetraborate, and boric acid.
  • solubilizing agent examples include non-ionic surfactants such as polyoxyethylenesorbitan monooleate (polysorbate 80), polyoxyethylenemonostearate, polyethylene glycol and polyoxyethylene hydrogenated castor oil.
  • preservative examples include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, p-hydroxybenzoates such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and butyl p-hydroxybenzoate, benzyl alcohol, phenetyl alcohol, sorbic acid and salts thereof, thimerosal, chlorobutanol and sodium dehydroacetate.
  • quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride
  • p-hydroxybenzoates such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and butyl p-hydroxybenzoate
  • benzyl alcohol phenetyl alcohol, sorbic acid and
  • thickener examples include polyvinylpyrrolidone, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof.
  • chelating agent examples include disodium edetate and citric acid.
  • pH-adjusting agent examples include hydrochloric acid, citric acid, phosphoric acid, acetic acid, tartaric acid, sodium hydroxide, potassium hydroxide, sodium carbonate and sodium hydrogencarbonate.
  • aromatic agent examples include 1-menthol, borneol, camphor (e.g. dl-camphor) and eucalyptus oil.
  • the liquid preparation of the present invention is used as an eye drop, collunarium and the like.
  • its pH is generally adjusted to about 6.0-8.5, preferably about 7.0-8.0
  • its pH is generally adjusted to about 6.0-8.5, preferably about 7.0-8.0.
  • the dose of the liquid preparation of the present invention when used, for example, as an eye drop, is an amount sufficient to effectively resolve ophthalmic inflammation, and varies depending on symptoms and the kind of inflammation.
  • the dose is generally 5.0-1,000 ⁇ g/administration, preferably 25-500 ⁇ g/administration, which is administered 2 to 5 times a day as appropriate.
  • BHT or sodium thiosulfate was added to a basic formulation solution pranoprofen, 0.1 w/v %; boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount!, and the mixture was filled in 5 ml polypropylene containers. The containers were left standing in the dark at room temperature for 39 months. The residual content of pranoprofen in the containers was determined by high performance liquid chromatography. The results are shown in Table 2.
  • a solution of 0.1 w/v % pranoprofen boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount! was filled in 5 ml polypropylene containers and the containers were tightly sealed.
  • the containers were enclosed together with iron oxide (Ageless Z-30, manufactured by Mitsubishi Gas Chemical Company, Inc.) as a deoxygenating agent, with the use of a multi-layer film of polypropylene/poly(vinyl alcohol)/polyethylene and left standing at room temperature for 30 months.
  • the residual content of pranoprofen in the containers was determined with time by high performance liquid chromatography. The results are shown in Table 4.
  • (1), (2), (3), (4), (5) and (6) were dissolved in about 80 ml of (7), and pH was adjusted to 7.0 with (3). (7) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for an eye drop, which comprised 0.5% BHT.
  • (1), (2), (3), (4), (5) and (6) were dissolved in about 80 ml of (7), and pH was adjusted to 7.0 with (3). (7) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for an eye drop.
  • the container and iron oxide (Ageless Z-30; manufactured by Mitsubishi Gas Chemical Company, Inc.) were enclosed with a multi-layer film of polypropylene/poly(vinyl alcohol)/polyethylene.
  • (1), (2), (3), (4) and (5) were dissolved in about 70 ml of (9).
  • (6), (7) and (8) were admixed and uniformly dispersed in about 20 ml of (9) heated to about 60° C. This dispersion was added to the above-mentioned solution.
  • the pH of the mixture was adjusted to 7.5 with (3) and (9) was added to make the total amount 100 ml.
  • the mixture was filled in a 15 ml PET container for an eye drop and enclosed to avoid light.
  • (1), (2), (3), (4), (5) and (6) were dissolved in about 70 ml of (8), and pH was adjusted to 7.5 with (7).
  • (8) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for a collunarium.
  • (1), (2), (3), (4), (5) and (6) were dissolved in about 80 ml of (8), and pH was adjusted to 7.0 with (7).
  • (8) was added to make the total amount 100 ml and the mixture was filled in a 8 ml PE container for a collunarium.
  • the container and iron oxide (Ageless Z-30; manufactured by Mitsubishi Gas Chemical Company, Inc.) were enclosed with a multi-layer film of polypropylene/poly(vinyl alcohol )/polyethylene.
  • the decomposition of the active ingredient pranoprofen is remarkably suppressed.
  • pranoprofen becomes stable to light, thus permitting long-term preservation of an aqueous solution (preparation) of pranoprofen.

Abstract

A method for stabilizing pranoprofen, comprising placing an aqueous solution of pranoprofen in coexistence with an antioxidant, or placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen, and a stable aqueous preparation of pranoprofen, comprising pranoprofen and an antioxidant. According to the present invention, the decomposition of pranoprofen in an aqueous solution of pranoprofen is remarkably suppressed. In particular, pranoprofen becomes stable to light, thus permitting long-term preservation of an aqueous solution, specifically a liquid preparation, of pranoprofen.

Description

This is a divisional application of Ser. No. 08/404,102, filed Mar. 14, 1995.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for stabilizing pranoprofen having anti-inflammatory activity, in an aqueous solution of pranoprofen, and to a liquid preparation comprising, as an active ingredient, pranoprofen which is stabilized by adding an antioxidant.
2. Description of Related Art
Pranoprofen having a chemical name of α-methyl-5H- 1!benzopyrano 2,3-b!pyridine-7-acetic acid exhibits prominent anti-inflammatory action, analgesic action and antipyretic action. It is a non-steroidal anti-inflammatory drug having a wider safety margin, and is commercially available by the product name of Niflan (trademark). The properties and production method thereof are described in U.S. Pat. No. 3,931,295.
There has also been proposed an eye drop containing pranoprofen as an anti-inflammatory active ingredient and boric acid as an isotonizing agent, as being useful for, in particular, herpesvirus eye diseases (U.S. Pat. No. 4,607,038).
However, pranoprofen is unstable in an aqueous solution state, particularly to light, and is gradually decomposed during long-term preservation.
It is therefore an object of the present invention to provide a method for stabilizing pranoprofen in an aqueous solution state.
Another object of the present invention is to provide an aqueous solution of pranoprofen, wherein decomposition of pranoprofen is suppressed.
SUMMARY OF THE INVENTION
According to the present invention, it has now been found that decomposition of pranoprofen can be markedly suppressed by placing an aqueous solution of pranoprofen in coexistence with an antioxidant, or placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen.
That is, the present invention and preferable modes thereof are as follows.
(1) A method for stabilizing pranoprofen, comprising placing an aqueous solution of pranoprofen in coexistence with an antioxidant.
(2) A method for stabilizing pranoprofen according to (1), comprising adding an antioxidant to an aqueous solution of pranoprofen.
(3) A method for stabilizing pranoprofen according to (2), comprising adding an antioxidant at a ratio to pranoprofen of 0.0002-5.0 by weight.
(4) A method for stabilizing pranoprofen according to (1), comprising sealing an aqueous solution of pranoprofen in a container formed from a material comprising an antioxidant.
(5) A method for stabilizing pranoprofen according to (4), comprising adding an antioxidant to a material of the container at a ratio to the material of 0.0001-0.005 by weight.
(6) A method for stabilizing pranoprofen according to (4), wherein the container is made of polypropylene.
(7) A method for stabilizing pranoprofen according to (2), wherein the antioxidant is at least one compound selected from the group consisting of alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.
(8) A method for stabilizing pranoprofen according to (7), wherein the alkylphenol is at least one compound selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
(9) A method for stabilizing pranoprofen according to (7), wherein the benzopyran derivative is at least one member selected from the group consisting of L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! and salts thereof.
(10) A method for stabilizing pranoprofen according to (7), wherein the amino acid is at least one member selected from the group consisting of methionine, tryptophan and histidine.
(11) A method for stabilizing pranoprofen according to any one of (4)-(6), wherein the antioxidant is at least one alkylphenol.
(12) A method for stabilizing pranoprofen according to (11), wherein the alkylphenol is at least one member selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
(13) A method for stabilizing pranoprofen, comprising placing an aqueous solution of pranoprofen under the conditions of limited supply of oxygen.
(14) A method for stabilizing pranoprofen according to (13), comprising sealing a container, in which an aqueous solution of pranoprofen has been sealed, in a container or enclosing the container with a sheet, together with a deoxygenating agent.
(15) A method for stabilizing pranoprofen according to (13), comprising sealing an aqueous solution of pranoprofen in a container having a low oxygen permeability or enclosing the solution with a sheet having a low oxygen permeability.
(16) A stabilizing method according to (1), wherein the aqueous solution of pranoprofen is an eye drop or a collunarium.
(17) A stabilizing method according to (13), wherein the aqueous solution of pranoprofen is an eye drop or a collunarium.
(18) A stable liquid preparation of pranoprofen, comprising pranoprofen and an antioxidant.
(19) The liquid preparation of (18), wherein the antioxidant is at least one compound selected from the group consisting of alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.
(20) The liquid preparation of (19), wherein the alkylphenol is at least one member selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
(21) The liquid preparation of (19), wherein the benzopyran derivative is at least one compound selected from the group consisting of L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! and salts thereof.
(22) The liquid preparation of (19), wherein the amino acid is at least one member selected from the group consisting of methionine, tryptophan and histidine.
(23) The liquid preparation of (18), comprising an antioxidant at a ratio to pranoprofen of 0.0002-5.0 by weight.
(24) The liquid preparation of (18), which is an eye drop.
(25) The liquid preparation of (18), which is a collunarium.
DETAILED DESCRIPTION OF THE INVENTION
The first mode of the stabilizing method of the present invention is placing an aqueous solution of pranoprofen in coexistence with an antioxidant, which is realized by, for example, (i) adding an antioxidant to an aqueous solution of pranoprofen (Mode I) or (ii) sealing an aqueous solution of pranoprofen in a container formed from a material comprising an antioxidant (Mode II). The Modes I and II may be used in combination.
The antioxidant to be used in Mode I includes, for example, alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.
Examples of alkylphenol include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), n-propyl gallate and catechol, with preference given to BHT and BHA.
Examples of benzopyran derivative include tocopherol, tocol, L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! and salts thereof, with preference given to L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! potassium salt (EPC-K1).
Amino acid is, for example, methionine, tryptophan or histidine, with preference given to methionine and tryptophan.
When an antioxidant is added to an aqueous solution of pranoprofen according to Mode I, the antioxidant is generally added at a ratio to pranoprofen of 0.0002-5.0 by weight, preferably 0.002-2.5 by weight.
When an aqueous solution of pranoprofen is sealed in a container formed from a material comprising an antioxidant, according to Mode II, the container is, for example, generally a plastic container such as the one composed of polyolefin e.g. polyethylene (PE) and polypropylene (PP)!, with preference given to the one composed of PP.
An antioxidant is added to the material of the container at a ratio to the material of, for example, 0.0001-0.005 by weight, preferably 0.0005-0.005 by weight.
In the Mode II, the antioxidant to be used is, for example, a phenol such as alkylphenol, alkyldiphenol or thiobisalkylphenol.
Examples of alkylphenol include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), n-propyl gallate, stearyl β-(3,5-di-t-butyl-4-hydroxyphenyl)propionate, tetrakis 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyloxymethyl!methane, 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1H,2H,3H-triazine-2,4,6-trione, 1,3,5-tris (3,5-di-tert-butyl-4-hydroxybenzyl)-2,4,6-trimethyl!benzene and 3,9-bis 2-(3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy)-1,1-dimethylethyl!-2,4,8,10-tetraoxaspiro 5.5!undecane, with preference given to BHT and BHA.
Examples of alkyldiphenol include 2,2'-methylenebis(4-methyl-6-tert-butylphenol), 4,4'-butylidenebis(2-tert-butyl-5-methylphenol) and 2-tert-butyl-6-(3-tert-butyl-2-hydroxy-5-methylbenzyl)-4-methylphenyl acrylate.
Examples of thiobisalkylphenol include 4,4'-thiobis(2-tert-butyl-5-methylphenol).
The second mode of the stabilizing method of the present invention is placing an aqueous solution of pranoprofen under the conditions of limited oxygen supply. For example, a container containing an aqueous solution of pranoprofen sealed therein is sealed in another container or enclosed with a sheet in coexistence with a deoxygenating agent (Mode III), or an aqueous solution of pranoprofen is sealed in a container having a low oxygen permeability, or enclosed with a sheet having a low oxygen permeability (Mode IV).
In the Mode III, the container for sealing an aqueous solution of pranoprofen is subject to no particular limitation as long as it can seal an aqueous solution of pranoprofen, and is preferably exemplified by a container formed from a material containing an antioxidant, such as those exemplified for the above-mentioned Mode II, and a container having a low oxygen permeability to be mentioned below.
The deoxygenating agent to be used in Mode III is exemplified by iron powder, iron oxide, ascorbic acid and catechol, with preference given to iron oxide. The deoxygenating agent is preferably packed in a bag etc. made of an oxygen-permeable material and put to use.
The container and the sheet to enclose a container, in which an aqueous solution of pranoprofen has been sealed, together with a deoxygenating agent according to Mode III, are not subject to any particular limitation as long as they can enclose both the container, in which an aqueous solution of pranoprofen has been sealed, and a deoxygenating agent in such a manner that the outside air is shut off from them. Examples of the container include plastic containers and glass containers, and examples of the sheet include plastic sheets and aluminum sheets. The materials for such containers and sheets may contain an antioxidant, as exemplified in the above-mentioned Mode II, or may have a low oxygen permeability as discussed below. Also, an antioxidant may be added to an aqueous solution of pranoprofen in Mode III.
The container and the sheet having low oxygen permeability, which are to be used in Mode IV, are preferably made from a material having an oxygen permeability of not more than 120 cc/m2 ·24 hr·atom 20° C.·90% relative humidity (RH), thickness of material 25 μm!, preferably not more than 70 cc/m2 ·24 hr·atom (20° C.·90% RH, thickness of material 25 μm), such as those made from acrylonitrile resins e.g. acrylonitrile styrene (AS) and acrylonitrile butadiene styrene (ABS)! and polyethylene terephthalate (PET), with particular preference given to those made from PET.
The solvent to be used to prepare a liquid preparation and an aqueous solution of pranoprofen of the present invention is exemplified by sterile purified water, in particular, distilled water for injection. The concentration of the active ingredient pranoprofen is generally 0.01-2.0 w/v %, preferably 0.05-1.0 w/v %, which is increased or decreased as appropriate according to the object of use.
The antioxidant to be used for the liquid preparation of pranoprofen of the present invention is exemplified by those mentioned for Mode I.
The liquid preparation of the present invention may further contain various additives on demand, such as buffers, isotonizing agents, solubilizing agents, preservatives, thickeners, chelating agents, pH adjusting agents and aromatic agents.
Examples of buffer include phosphate buffer (e.g. sodium dihydrogenphosphate-disodium hydrogenphosphate and potassium dihydrogenphosphate-potassium hydroxide), borate buffer (e.g. boric acid-sodium tetraborate), citrate buffer (e.g. sodium citrate-sodium hydroxide), tartrate buffer (e.g. tartaric acid-sodium tartrate), acetate buffer (e.g. acetic acid-sodium acetate), carbonate buffer (e.g. sodium carbonate-citric acid and sodium carbonate-boric acid) and amino acid (e.g. sodium glutamate and ε-aminocaproic acid).
When the liquid preparation of pranoprofen is used as an eye drop, it is preferable that borate buffer, acetate buffer or carbonate buffer be used to decrease irritation.
Examples of isotonizing agent include saccharides such as sorbitol, glucose and mannitol, polyhydric alcohols such as glycerol and propylene glycol, salts such as sodium chloride and sodium tetraborate, and boric acid.
Examples of solubilizing agent include non-ionic surfactants such as polyoxyethylenesorbitan monooleate (polysorbate 80), polyoxyethylenemonostearate, polyethylene glycol and polyoxyethylene hydrogenated castor oil.
Examples of preservative include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, p-hydroxybenzoates such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and butyl p-hydroxybenzoate, benzyl alcohol, phenetyl alcohol, sorbic acid and salts thereof, thimerosal, chlorobutanol and sodium dehydroacetate.
Examples of thickener include polyvinylpyrrolidone, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof.
Examples of chelating agent include disodium edetate and citric acid.
Examples of pH-adjusting agent include hydrochloric acid, citric acid, phosphoric acid, acetic acid, tartaric acid, sodium hydroxide, potassium hydroxide, sodium carbonate and sodium hydrogencarbonate.
Examples of aromatic agent include 1-menthol, borneol, camphor (e.g. dl-camphor) and eucalyptus oil.
The liquid preparation of the present invention is used as an eye drop, collunarium and the like. When used as an eye drop, its pH is generally adjusted to about 6.0-8.5, preferably about 7.0-8.0, and when used as a collunarium, its pH is generally adjusted to about 6.0-8.5, preferably about 7.0-8.0.
While the method for producing the liquid preparation of the present invention varies depending on the kind of liquid preparation, a known method for each liquid preparation can be used.
The dose of the liquid preparation of the present invention, when used, for example, as an eye drop, is an amount sufficient to effectively resolve ophthalmic inflammation, and varies depending on symptoms and the kind of inflammation. The dose is generally 5.0-1,000 μg/administration, preferably 25-500 μg/administration, which is administered 2 to 5 times a day as appropriate.
The present invention is described in more detail in the following by referring to Experimental Examples and Examples.
EXPERIMEMTAL EXAMPLE 1 Stability test--No. 1!
A solution of 0.1 w/v % pranoprofen boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount! was filled in 5 ml polypropylene containers manufactured by adding BHT to 0.05, 0.1 or 0.5 w/v % oxygen permeability of 25 μm thick test sample, 3,800 cc/m2 ·24 hr·atom (20° C.·90% RH); Gas Permeation Test Method of Plastic Film and Sheet of Japanese Industrial Standards, the equal pressure method Japanese Standards Association, JIS Handbook, p 400, Tokyo (1991)!! and 15 ml polyethylene terephthalate containers oxygen permeability of 25 μm thick test samples, 63 cc/m2 ·24 hr·atom (20° C.·90% RH); Gas Permeation Test Method of Plastic Film and Sheet of Japanese Industrial Standards, the equal pressure method Japanese Standards Association, JIS Handbook, p 400, Tokyo (1991)!!, and left standing in the dark at room temperature for 36 months. The residual content of pranoprofen in the containers was determined with time by high performance liquid chromatography. The results are shown in Table 1.
              TABLE 1
______________________________________
Residual content of pranoprofen (%)
        On prepa-
                 3       6     12    24    36
Container
        ration   months  months
                               months
                                     months
                                           months
______________________________________
PP (control)
        100.0    95.6    93.9  --    81.9  78.5
PP-05   100.0    100.4   99.3  99.0  98.5  100.2
PP-01   100.0    100.4   98.3  98.1  95.4  96.0
PP-005  100.0    100.4   98.3  97.0  93.2  93.3
PET     100.0    99.5    101.0 100.3 100.8 99.4
______________________________________
 PP: polypropylene container without BHT oxygen permeability, 3800
 cc/m.sup.2 · 24 hr · atom (20° C. · 90%
 RH, 25 μm)
 PP05: polypropylene container containing 0.5% BHT
 PP01: polypropylene container containing 0.1% BHT
 PP005: polypropylene container containing 0.05% BHT
 PET: polyethylene terephthalate container without BHT oxygen permeability
 63 cc/m.sup.2 · 24 hr · atom (20° C. ·
 90% RH, 25 μm)
As is evident from Table 1, superior suppression of decomposition of pranoprofen was achieved by preserving pranoprofen in the containers (PP) formed from a material containing BHT and in the container (PET) having a low oxygen permeability.
EXPERIMENTAL EXAMPLE 2 Stability test--No. 2!
BHT or sodium thiosulfate was added to a basic formulation solution pranoprofen, 0.1 w/v %; boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount!, and the mixture was filled in 5 ml polypropylene containers. The containers were left standing in the dark at room temperature for 39 months. The residual content of pranoprofen in the containers was determined by high performance liquid chromatography. The results are shown in Table 2.
              TABLE 2
______________________________________
                  Residual content of pranoprofen
         Concentration
                  (%)
Compound added
           (%)        On preparation
                                 after 39 months
______________________________________
Control (not added)
           0          100.0      77.0
BHT        0.0004     100.0      99.6
"          0.0001     100.0      94.7
sodium thiosulfate
           0.1        100.0      93.0
______________________________________
As is evident from Table 2, superior suppression of decomposition of pranoprofen was achieved by the addition of respective antioxidants.
EXPERIMENTAL EXAMPLE 3 Stability test--No. 3!
BHT, BHA, L-ascorbic acid 2- 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate! potassium salt (EPC-KI), methionine, tryptophan or histidine was added to a basic formulation solution pranoprofen, 0.05 w/v %; boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount!, and the mixture was filled in colorless 15 ml polyethylene terephthalate containers. The containers were left standing under a fluorescent lamp (20 W). When the total irradiation reached 100,000 lux·hr, the residual content of pranoprofen in the containers was determined by high performance liquid chromatography. The results are shown in Table 3.
              TABLE 3
______________________________________
                Residual content of pranoprofen
                (%)
           Concentration
                      On         after irradiation of
Compound added
           (%)        preparation
                                 100,000 lux · hr
______________________________________
Control (not added)
           0          100.0      52.5
BHT        0.005      100.0      98.0
"          0.002      100.0      96.6
"          0.0002     100.0      70.8
BHA        0.002      100.0      92.8
EPC-K.sub.1
           0.05       100.0      79.1
"          0.01       100.0      70.5
"          0.001      100.0      68.2
methionine 0.24       100.0      95.2
tryptophan 0.06       100.0      96.9
histidine  0.13       100.0      75.9
______________________________________
As is evident from Table 3, the decomposition of pranoprofen caused by the exposure to the light was markedly suppressed by the addition of respective antioxidants.
EXPERIMENTAL EXAMPLE 4 Stability test--No. 4!
A solution of 0.1 w/v % pranoprofen boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount! was filled in 5 ml polypropylene containers and the containers were tightly sealed. The containers were enclosed together with iron oxide (Ageless Z-30, manufactured by Mitsubishi Gas Chemical Company, Inc.) as a deoxygenating agent, with the use of a multi-layer film of polypropylene/poly(vinyl alcohol)/polyethylene and left standing at room temperature for 30 months. The residual content of pranoprofen in the containers was determined with time by high performance liquid chromatography. The results are shown in Table 4.
              TABLE 4
______________________________________
        Residual content of pranoprofen (%)
                     2       6     9     30
Enclosing On preparation
                     months  months
                                   months
                                         months
______________________________________
Unenclosed
          100.0      95.1    89.4  92.0  80.3
Film-enclosed
          100.0      98.1    97.6  97.2  101.0
(deoxygenator)
Film-enclosed
          100.0      95.0    93.4  89.5  88.5
(N.sub.2 substitution)
______________________________________
 Containers used: polypropylene containers without BHT
 Film: multilayer film of polypropylene/poly(vinyl alcohol)/polyethylene
 deoxygenating agent: iron oxide (Ageless Z30, manufactured by Mitsubishi
 Gas Chemical Company, Inc.)
As is evident from Table 4, marked suppression of decomposition of pranoprofen was achieved by sealing a container, in which an aqueous solution of pranoprofen had been sealed, together with a deoxygenating agent.
EXAMPLE 1 Eye 
______________________________________
 (1) Pranoprofen        0.2      g
 (2) Disodium hydrogenphosphate
                        0.5      g
 (3) Sodium dihydrogenphosphate
                        0.1      g
 (4) Polyoxyethylene hydrogenated castor oil 60
                        0.1      g
 (5) Poly(vinyl alcohol)
                        0.2      g
 (6) Sodium chloride    0.8      g
 (7) Benzethonium chloride
                        0.007    g
 (8) BHT                0.01     g
 (9) Sodium hydroxide   appropriate amount
(10) Sterile purified water
                        appropriate amount
Total                   100      ml
______________________________________
(5) was added to about 70 ml of (10) and the mixture was stirred with heating to about 70° C. for dissolution. (4) and (8) were added to this solution and the mixture was admixed until it became a uniform dispersion. The mixture was cooled to room temperature. (1), (2), (3), (6) and (7) were dissolved in this solution and pH was adjusted to 7.2 with (9). (10) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PE container for an eye drop.
EXAMPLE 2 Eye 
______________________________________
(1) Pranoprofen  0.4          g
(2) Sodium chloride
                 0.5          g
(3) Polysorbate 80
                 0.15         g
(4) Polyethylene glycol
                 0.5          g
(5) Citric acid  0.2          g
(6) Benzalkonium chloride
                 0.009        g
(7) Sodium thiosulfate
                 0.01         g
(8) Sodium carbonate
                 appropriate amount
(9) Sterile purified water
                 appropriate amount
Total            100          ml
______________________________________
(1), (2), (3), (4), (5), (6) and (7) were dissolved in about 70 ml of (9) and pH was adjusted to 8.0 with (8). (9) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for an eye drop.
EXAMPLE 3 Eye 
______________________________________
(1) Pranoprofen     0.1        g
(2) Potassium dihydrogenphosphate
                    0.3        g
(3) Conc. glycerol  2.6        g
(4) Potassium hydroxide
                    appropriate amount
(5) Disodium edetate
                    0.01       g
(6) EPC-K.sub.1     0.05       g
(7) Methyl p-hydroxybenzoate
                    0.026      g
(8) Propyl p-hydroxybenzoate
                    0.014      g
(9) Sterile purified water
                    appropriate amount
Total               100        ml
______________________________________
About 80 ml of (9) was heated to about 90° C. and (7) and (8) were dissolved. The mixture was cooled to room temperature. An appropriate amount of (4) was dissolved and then, (1), (2), (3), (5) and (6) were dissolved. Its pH was adjusted to 6.5 with (4). (9) was added to make the total amount 100 ml and the mixture was filled in a 10 ml polycarbonate container for an eye drop.
EXAMPLE 4 Eye 
______________________________________
(1) Pranoprofen  0.1          g
(2) Boric acid   1.6          g
(3) Sodium tetraborate
                 appropriate amount
(4) Disodium edetate
                 0.01         g
(5) Polysorbate 80
                 0.15         g
(6) Benzalkonium chloride
                 0.007        g
(7) Sterile purified water
                 appropriate amount
Total            100          ml
______________________________________
(1), (2), (3), (4), (5) and (6) were dissolved in about 80 ml of (7), and pH was adjusted to 7.0 with (3). (7) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for an eye drop, which comprised 0.5% BHT.
EXAMPLE 5 Eye 
______________________________________
(1) Pranoprofen  0.1          g
(2) Boric acid   1.6          g
(3) Sodium tetraborate
                 appropriate amount
(4) Disodium edetate
                 0.01         g
(5) Polysorbate 80
                 0.15         g
(6) Benzalkonium chloride
                 0.007        g
(7) Sterile purified water
                 appropriate amount
Total            100          ml
______________________________________
(1), (2), (3), (4), (5) and (6) were dissolved in about 80 ml of (7), and pH was adjusted to 7.0 with (3). (7) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for an eye drop. The container and iron oxide (Ageless Z-30; manufactured by Mitsubishi Gas Chemical Company, Inc.) were enclosed with a multi-layer film of polypropylene/poly(vinyl alcohol)/polyethylene.
EXAMPLE 6 Eye 
______________________________________
(1) Pranoprofen  0.05         g
(2) Boric acid   1.6          g
(3) Sodium tetraborate
                 appropriate amount
(4) Disodium edetate
                 0.01         g
(5) Benzalkonium chloride
                 0.005        g
(6) 1-menthol    0.002        g
(7) dl-camphor   0.0005       g
(8) Polysorbate 80
                 0.1          g
(9) Sterile purified water
                 appropriate amount
Total            100          ml
______________________________________
(1), (2), (3), (4) and (5) were dissolved in about 70 ml of (9). (6), (7) and (8) were admixed and uniformly dispersed in about 20 ml of (9) heated to about 60° C. This dispersion was added to the above-mentioned solution. The pH of the mixture was adjusted to 7.5 with (3) and (9) was added to make the total amount 100 ml. The mixture was filled in a 15 ml PET container for an eye drop and enclosed to avoid light.
EXAMPLE 7 
______________________________________
(1) Pranoprofen  0.4          g
(2) Sodium citrate
                 0.2          g
(3) Polysorbate 80
                 0.1          g
(4) Glycerol     2.6          g
(5) Benzethonium chloride
                 0.007        g
(6) Methionine   0.24         g
(7) Sodium hydroxide
                 appropriate amount
(8) Sterile purified water
                 appropriate amount
Total            100          ml
______________________________________
(1), (2), (3), (4), (5) and (6) were dissolved in about 70 ml of (8), and pH was adjusted to 7.5 with (7). (8) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for a collunarium.
EXAMPLE 8 
______________________________________
(1) Pranoprofen  1.0          g
(2) Boric acid   1.2          g
(3) Sodium tetraborate
                 0.8          g
(4) Disodium edetate
                 0.01         g
(5) Polysorbate 80
                 0.15         g
(6) Benzalkonium chloride
                 0.007        g
(7) Sodium hydroxide
                 appropriate amount
(8) Sterile purified water
                 appropriate amount
Total            100          ml
______________________________________
(1), (2), (3), (4), (5) and (6) were dissolved in about 80 ml of (8), and pH was adjusted to 7.0 with (7). (8) was added to make the total amount 100 ml and the mixture was filled in a 8 ml PE container for a collunarium. The container and iron oxide (Ageless Z-30; manufactured by Mitsubishi Gas Chemical Company, Inc.) were enclosed with a multi-layer film of polypropylene/poly(vinyl alcohol )/polyethylene.
According to the present invention, the decomposition of the active ingredient pranoprofen is remarkably suppressed. In particular, pranoprofen becomes stable to light, thus permitting long-term preservation of an aqueous solution (preparation) of pranoprofen.

Claims (4)

What is claimed is:
1. A method for stabilizing pranoprofen, comprising sealing an aqueous solution of pranoprofen in a container formed from a mixture comprising a material for the container and at least one alkylphenol antioxidant.
2. The method of claim 1, wherein the alkylphenol is at least one member selected from a group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
3. The method of claim 1, wherein the weight ratio of the antioxidant to the material is 0.0001-0.005:1.
4. The method of claim 1, wherein the container is made of polypropylene.
US08/873,924 1994-03-15 1997-06-12 Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen Expired - Fee Related US5889030A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/873,924 US5889030A (en) 1994-03-15 1997-06-12 Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP4418494 1994-03-15
US40410295A 1995-03-14 1995-03-14
US08/873,924 US5889030A (en) 1994-03-15 1997-06-12 Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US40410295A Division 1994-03-15 1995-03-14

Publications (1)

Publication Number Publication Date
US5889030A true US5889030A (en) 1999-03-30

Family

ID=12684495

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/779,604 Expired - Fee Related US5856345A (en) 1994-03-15 1997-01-07 Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen
US08/873,924 Expired - Fee Related US5889030A (en) 1994-03-15 1997-06-12 Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/779,604 Expired - Fee Related US5856345A (en) 1994-03-15 1997-01-07 Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen

Country Status (19)

Country Link
US (2) US5856345A (en)
EP (2) EP0672414B1 (en)
KR (1) KR100338851B1 (en)
CN (1) CN1091597C (en)
AT (1) ATE297206T1 (en)
AU (1) AU707119B2 (en)
BR (1) BR9501081A (en)
CA (1) CA2144591A1 (en)
DE (1) DE69534258T2 (en)
EE (1) EE9500015A (en)
ES (1) ES2240966T3 (en)
FI (1) FI951190A (en)
HU (1) HUT71245A (en)
LT (1) LT3969B (en)
LV (1) LV10922B (en)
NO (1) NO950970L (en)
PL (1) PL179534B1 (en)
RU (1) RU2148402C1 (en)
TW (1) TW358812B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107429A1 (en) * 2002-07-31 2005-05-19 Masayo Higashiyama Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
US7125497B1 (en) * 2003-05-22 2006-10-24 Sandia Corporation Reactive formulations for a neutralization of toxic industrial chemicals
US20140045948A1 (en) * 2012-02-27 2014-02-13 Rohto Pharmaceutical Co., Ltd. Kit of ophthalmic composition
US20140243419A1 (en) * 2013-02-19 2014-08-28 Rohto Pharmaceutical Co., Ltd. Mucosally-applied agent for prevention, amelioration or treatment of retinal disease
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
CN115677733A (en) * 2022-12-20 2023-02-03 济南宣正药业有限公司 Compound for pranoprofen quality research and preparation method and application thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
WO2000032157A1 (en) * 1998-12-02 2000-06-08 Copa Distributors, Llc Gradual hair relaxation composition
AU2003257982A1 (en) * 2002-07-31 2004-02-16 Pharmacia Corporation Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
DE122011100019I1 (en) 2003-01-21 2011-11-03 Senju Pharma Co Aqueous, liquid preparation with 2-amino-3- (4-bromobenzoyl) phenylacetic acid.
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
WO2004112837A1 (en) * 2003-05-23 2004-12-29 Hisamitsu Pharmaceutical Co., Inc. PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR
ES2363964B1 (en) 2009-11-20 2012-08-22 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
CN104010661B (en) * 2011-12-27 2017-06-06 千寿制药株式会社 The stabilization method of preparation and dibutyl hydroxy toluene containing dibutyl hydroxy toluene
JP5340498B1 (en) * 2013-03-11 2013-11-13 千寿製薬株式会社 Ophthalmic composition for soft contact lenses
WO2014192737A1 (en) * 2013-05-30 2014-12-04 千寿製薬株式会社 Method for stabilizing chlorpheniramine and salt thereof
TW201540292A (en) * 2014-03-10 2015-11-01 Senju Pharma Co Method for stabilizing dibutylhydroxytoluene
TWI644663B (en) * 2014-03-10 2018-12-21 日商千壽製藥股份有限公司 Method for stabilizing dibutylhydroxytoluene, and products containing dibutylhydroxytoluene (1)
AR102172A1 (en) * 2015-10-05 2017-02-08 Química Luar S R L A BACTERICIDE AND VIRUCIDE PHARMACEUTICAL COMPOSITION
KR102478553B1 (en) * 2018-02-28 2022-12-16 한림제약(주) Eye drop formulation in a solution form comprising a benzopyran derivative or pharmaceutically acceptable salt therof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2839752A1 (en) * 1977-11-07 1979-05-10 Toko Yakuhin Kogyo Kk PHARMACEUTICAL PREPARATION FOR EYE INJURY
US4525348A (en) * 1983-12-19 1985-06-25 Yoshitomi Pharmaceutical Industries, Ltd. Pranoprofen gelled ointment
US4607038A (en) * 1984-03-01 1986-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Ophthalmic pranoprofen compositions
WO1986006629A2 (en) * 1985-05-17 1986-11-20 Postley John E Ascorbic acid for treatment of sino-nasal congestion
EP0258865A2 (en) * 1986-09-04 1988-03-09 Vision Pharmaceuticals, Incorporated Aqueous opthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
EP0471084A1 (en) * 1990-03-02 1992-02-19 Shiseido Company Limited Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
US5110492A (en) * 1985-05-24 1992-05-05 Irene Casey Cleaner and disinfectant with dye
WO1992020376A1 (en) * 1991-05-11 1992-11-26 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption promoter composition and external preparation for percutaneous administration
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931295A (en) 1974-07-23 1976-01-06 Universal Oil Products Company Hydroxylation of aromatic compounds
US4565851A (en) * 1983-04-25 1986-01-21 Eastman Kodak Company Containers having improved gas barrier properties
JPS61130222A (en) * 1984-11-30 1986-06-18 Kureha Chem Ind Co Ltd Antitumor agent
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
JPH05124092A (en) * 1991-11-06 1993-05-21 Chisso Corp Hollow container made of polyolefine
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2839752A1 (en) * 1977-11-07 1979-05-10 Toko Yakuhin Kogyo Kk PHARMACEUTICAL PREPARATION FOR EYE INJURY
GB2007091A (en) * 1977-11-07 1979-05-16 Toko Yakuhin Kogyo Kk Ophthalmic composition
US4525348A (en) * 1983-12-19 1985-06-25 Yoshitomi Pharmaceutical Industries, Ltd. Pranoprofen gelled ointment
US4607038A (en) * 1984-03-01 1986-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Ophthalmic pranoprofen compositions
WO1986006629A2 (en) * 1985-05-17 1986-11-20 Postley John E Ascorbic acid for treatment of sino-nasal congestion
US5110492A (en) * 1985-05-24 1992-05-05 Irene Casey Cleaner and disinfectant with dye
EP0258865A2 (en) * 1986-09-04 1988-03-09 Vision Pharmaceuticals, Incorporated Aqueous opthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
EP0471084A1 (en) * 1990-03-02 1992-02-19 Shiseido Company Limited Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
WO1992020376A1 (en) * 1991-05-11 1992-11-26 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption promoter composition and external preparation for percutaneous administration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 105, 1986, No. 105: 158837z. *
Chemical Abstracts, vol. 118, 1993 No. 118:66887f (Abstract of Reference AD). *
Patent Abstracts of Japan, unexamined applications, C field, vol. 10 No. 318, Oct. 29, 1986, p. 140 C 381 of JP A 61 130 222. *
Patent Abstracts of Japan, unexamined applications, C field, vol. 10 No. 318, Oct. 29, 1986, p. 140 C 381 of JP-A-61 130 222.

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107429A1 (en) * 2002-07-31 2005-05-19 Masayo Higashiyama Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8784789B2 (en) 2002-07-31 2014-07-22 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8883825B2 (en) 2002-07-31 2014-11-11 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US9849121B2 (en) 2002-07-31 2017-12-26 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US7125497B1 (en) * 2003-05-22 2006-10-24 Sandia Corporation Reactive formulations for a neutralization of toxic industrial chemicals
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
US20140045948A1 (en) * 2012-02-27 2014-02-13 Rohto Pharmaceutical Co., Ltd. Kit of ophthalmic composition
US20140243419A1 (en) * 2013-02-19 2014-08-28 Rohto Pharmaceutical Co., Ltd. Mucosally-applied agent for prevention, amelioration or treatment of retinal disease
CN115677733A (en) * 2022-12-20 2023-02-03 济南宣正药业有限公司 Compound for pranoprofen quality research and preparation method and application thereof

Also Published As

Publication number Publication date
LV10922B (en) 1996-08-20
NO950970D0 (en) 1995-03-14
PL307671A1 (en) 1995-09-18
CA2144591A1 (en) 1995-09-16
AU1485295A (en) 1995-09-21
EP1163906A3 (en) 2003-05-21
EE9500015A (en) 1995-12-15
ES2240966T3 (en) 2005-10-16
FI951190A0 (en) 1995-03-14
EP1163906A2 (en) 2001-12-19
TW358812B (en) 1999-05-21
CN1091597C (en) 2002-10-02
DE69534258T2 (en) 2006-05-04
AU707119B2 (en) 1999-07-01
PL179534B1 (en) 2000-09-29
US5856345A (en) 1999-01-05
LT3969B (en) 1996-05-27
BR9501081A (en) 1996-06-04
NO950970L (en) 1995-09-18
ATE297206T1 (en) 2005-06-15
DE69534258D1 (en) 2005-07-14
CN1111510A (en) 1995-11-15
FI951190A (en) 1995-09-16
EP0672414A3 (en) 1995-12-13
LT95028A (en) 1995-10-25
KR100338851B1 (en) 2002-10-12
HUT71245A (en) 1995-11-28
EP0672414A2 (en) 1995-09-20
HU9500772D0 (en) 1995-04-28
RU2148402C1 (en) 2000-05-10
KR950032201A (en) 1995-12-20
EP0672414B1 (en) 2005-06-08
LV10922A (en) 1995-12-20

Similar Documents

Publication Publication Date Title
US5889030A (en) Method for stabilizing pranoprofen and stable liquid preparation of pranaprofen
JP3021312B2 (en) Method for stabilizing pranoprofen and stable aqueous solution of pranoprofen
CA2326137C (en) Method for stabilizing pharmaceutical compositions by special use of an antioxidant
US10568850B2 (en) Norepinephrine compositions and methods therefor
KR101322527B1 (en) Eye drop preparation comprising xanthan gum and terpenoid
US5556848A (en) Ophthalmic suspension containing diflupredonate
EP1532981B1 (en) Stable eye drops containing latanoprost as the active ingredient
EP0299527B1 (en) Doxorubicin hydrochloride aqueous solutions
JP2005015368A (en) Method for stabilizing pranoprofen-containing aqueous liquid preparation
US3230143A (en) Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
JPH0640907A (en) Method for stabilizing vitamin a compound-dissolved aqueous solution
AU615454B2 (en) Doxorubicin hydrochloride nonaqueous solution
JP2008120764A (en) Prostaglandin aqueous ophthalmic solution
EP0372888B1 (en) Doxorubicin aqueous solutions
CN111526892B (en) Ophthalmic product and masking method
AU637801B2 (en) Intranasal administration of 3,3-disubstituted indolines

Legal Events

Date Code Title Description
CC Certificate of correction
AS Assignment

Owner name: WELFIDE CORPORATION, JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.;REEL/FRAME:011347/0303

Effective date: 20000401

AS Assignment

Owner name: MITSUBISHI PHARMA CORPORATION, JAPAN

Free format text: MERGER;ASSIGNOR:WELFIDE CORPORATION;REEL/FRAME:012698/0582

Effective date: 20011001

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20030330

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362